ロード中...
2380. Healthcare Resource Utilization for High-Risk Patients Treated With Dalbavancin in Physician Office Infusion Centers (POICs)
BACKGROUND: Medicare beneficiaries and patients (patients) ≥65 years comprise the highest risk for utilization of healthcare resources including emergency department (ED) visits and hospitalizations (hosp). Dalbavancin (DAL) is a long-acting lipoglycopeptide approved for treatment of bacterial skin...
保存先:
| 出版年: | Open Forum Infect Dis |
|---|---|
| 主要な著者: | , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Oxford University Press
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6255471/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ofid/ofy210.2033 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|